Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an update.
Race Oncology Ltd. announced a change in the director’s interest, with Megan Baldwin acquiring 45,470 options exercisable at $4.69, expiring on November 24, 2029. This issuance of options was approved at the annual general meeting, indicating a strategic move to align management interests with shareholder value, potentially impacting the company’s governance and stakeholder confidence.
More about Race Oncology Ltd.
Race Oncology Ltd. operates in the biotechnology industry, focusing on the development and commercialization of cancer therapies. The company is engaged in advancing its primary product, Bisantrene, a chemotherapy drug, with a market focus on addressing unmet medical needs in oncology.
Average Trading Volume: 546,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
Learn more about RAC stock on TipRanks’ Stock Analysis page.